ResMed/$RMD

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About ResMed

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Ticker

$RMD
Sector

Primary listing

NYSE

Employees

10,600

ResMed Metrics

BasicAdvanced
$39B
28.41
$9.51
0.77
$2.12
0.78%

What the Analysts think about ResMed

Analyst ratings (Buy, Hold, Sell) for ResMed stock.

Bulls say / Bears say

ResMed delivered 10% year-over-year revenue growth to $1.348 billion and 23% non-GAAP EPS growth in Q4 FY 2025, driven by 230 bps of gross margin expansion (Globe Newswire)
The May 2025 acquisition of VirtuOx enhances ResMed’s at-home diagnostic capabilities, streamlining patient access to sleep and respiratory testing within its digital care ecosystem (Globe Newswire)
Strong capital allocation in Q4 FY 2025 included a 13% dividend increase to $0.60/share and $100 million in share repurchases, supported by $539 million of operating cash flow (Globe Newswire)
Extended valuation at 23.7x expected earnings, near a three-year high, limits the margin of safety if growth decelerates (Barron's)
Ongoing regulatory uncertainties and sector underperformance in U.S. healthcare have weighed on stocks like ResMed, potentially dampening investor sentiment (Reuters)
The VirtuOx acquisition brings only an approximate $45 million annual revenue run rate—under 1% of ResMed’s consolidated revenue—indicating a limited near-term financial impact (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.

ResMed Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ResMed Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RMD

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

Sept18
ResMed
DividendPayment
$0.60Per share
FAQs